查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1459803

地中海貧血治療市場（治療類型：輸血、螯合療法、骨髓移植等）- 2023-2031 年全球產業分析、規模、佔有率、成長、趨勢與預測

Thalassemia Treatment Market (Treatment Type: Blood Transfusion, Chelation Therapy, Bone Marrow Transplantation, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 193 Pages | 商品交期: 2-10個工作天內

價格

地中海型貧血治療市場 - 報告範圍

TMR 關於全球地中海貧血治療市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球地中海貧血治療市場的收入2017-2031年期間，考慮2023年為基準年，2031年為預測年。報告中也提供了2023年至2031年全球地中海貧血治療市場的年複合成長率（CAGR %）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解地中海貧血治療市場。

市場概況
2022年市場價​​值 7.918 億美元
2031 年市場價值 15億美元
CAGR 7.3%

該報告深入探討了全球地中海貧血治療市場的競爭格局。全球地中海貧血治療市場的主要參與者已經確定，並且每位參與者都根據不同的屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球地中海貧血治療市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概述

  • 介紹
  • 概述
  • 市場動態
  • 2017-2031年全球市場分析與預測

第 5 章：關鍵見解

  • 管道分析
  • 主要產品/品牌分析
  • 主要併購
  • COVID-19 大流行對該行業的影響

第 6 章：全球市場分析與預測：依治療類型

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依治療類型，2017-2031
    • 輸血
    • 螯合療法
    • 骨髓移植
    • 其他
  • 市場吸引力分析：按治療類型

第 7 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2017-2031
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第 8 章：北美市場分析與預測

第 9 章：歐洲市場分析與預測

第 10 章：亞太市場分析與預測

第 11 章：拉丁美洲市場分析與預測

第 12 章：中東和非洲市場分析與預測

第 13 章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2022 年）
  • 公司簡介
    • Bluebird Bio, Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Celgene Corporation
    • Takeda Pharmaceuticals Company Limited
    • Incyte Corporation
    • Sanofi
    • Bellicum Pharmaceuticals
    • GSK plc
Product Code: TMRGL44462

Thalassemia Treatment Market - Scope of Report

TMR's report on the global thalassemia treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global thalassemia treatment market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global thalassemia treatment market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the thalassemia treatment market.

Market Snapshot
Market Value in 2022US$ 791.8 Mn
Market Value in 2031US$ 1.5 Bn
CAGR7.3%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global thalassemia treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global thalassemia treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global thalassemia treatment market.

The report delves into the competitive landscape of the global thalassemia treatment market. Key players operating in the global thalassemia treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global thalassemia treatment market profiled in this report.

Key Questions Answered in Global thalassemia treatment Market Report:

  • What is the sales/revenue generated by thalassemia treatment across all regions during the forecast period?
  • What are the opportunities in the global thalassemia treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Thalassemia Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global thalassemia treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global thalassemia treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global thalassemia treatment market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Thalassemia Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Thalassemia Treatment Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Thalassemia Treatment Market Analysis and Forecast, by Treatment Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 6.3.1. Blood Transfusion
    • 6.3.2. Chelation Therapy
    • 6.3.3. Bone Marrow Transplantation
    • 6.3.4. Others
  • 6.4. Market Attractiveness Analysis, by Treatment Type

7. Global Thalassemia Treatment Market Analysis and Forecast, by Region

  • 7.1. Key Findings
  • 7.2. Market Value Forecast, by Region, 2017-2031
    • 7.2.1. North America
    • 7.2.2. Europe
    • 7.2.3. Asia Pacific
    • 7.2.4. Latin America
    • 7.2.5. Middle East & Africa
  • 7.3. Market Attractiveness Analysis, by Region

8. North America Thalassemia Treatment Market Analysis and Forecast

  • 8.1. Introduction
  • 8.2. Key Findings
  • 8.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 8.3.1. Blood Transfusion
    • 8.3.2. Chelation Therapy
    • 8.3.3. Bone Marrow Transplantation
    • 8.3.4. Others
  • 8.4. Market Value Forecast, by Country, 2017-2031
    • 8.4.1. U.S.
    • 8.4.2. Canada
  • 8.5. Market Attractiveness Analysis
    • 8.5.1. By Treatment Type
    • 8.5.2. By Country

9. Europe Thalassemia Treatment Market Analysis and Forecast

  • 9.1. Introduction
  • 9.2. Key Findings
  • 9.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 9.3.1. Blood Transfusion
    • 9.3.2. Chelation Therapy
    • 9.3.3. Bone Marrow Transplantation
    • 9.3.4. Others
  • 9.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 9.4.1. Germany
    • 9.4.2. U.K.
    • 9.4.3. France
    • 9.4.4. Italy
    • 9.4.5. Spain
    • 9.4.6. Rest of Europe
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Treatment Type
    • 9.5.2. By Country/Sub-region

10. Asia Pacific Thalassemia Treatment Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 10.3.1. Blood Transfusion
    • 10.3.2. Chelation Therapy
    • 10.3.3. Bone Marrow Transplantation
    • 10.3.4. Others
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.4.1. China
    • 10.4.2. Japan
    • 10.4.3. India
    • 10.4.4. Australia & New Zealand
    • 10.4.5. Rest of Asia Pacific
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Treatment Type
    • 10.5.2. By Country/Sub-region

11. Latin America Thalassemia Treatment Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 11.3.1. Blood Transfusion
    • 11.3.2. Chelation Therapy
    • 11.3.3. Bone Marrow Transplantation
    • 11.3.4. Others
  • 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.4.1. Brazil
    • 11.4.2. Mexico
    • 11.4.3. Rest of Latin America
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Treatment Type
    • 11.5.2. By Country/Sub-region

12. Middle East & Africa Thalassemia Treatment Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 12.3.1. Blood Transfusion
    • 12.3.2. Chelation Therapy
    • 12.3.3. Bone Marrow Transplantation
    • 12.3.4. Others
  • 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.4.1. GCC Countries
    • 12.4.2. South Africa
    • 12.4.3. Rest of Middle East & Africa
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Treatment Type
    • 12.5.2. By Country/Sub-region

13. Competition Landscape

  • 13.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 13.2. Market Share Analysis, by Company (2022)
  • 13.3. Company Profiles
    • 13.3.1. Bluebird Bio, Inc.
      • 13.3.1.1. Company Overview
      • 13.3.1.2. Product Portfolio
      • 13.3.1.3. SWOT Analysis
      • 13.3.1.4. Financial Overview
      • 13.3.1.5. Strategic Overview
    • 13.3.2. Merck & Co., Inc.
      • 13.3.2.1. Company Overview
      • 13.3.2.2. Product Portfolio
      • 13.3.2.3. SWOT Analysis
      • 13.3.2.4. Financial Overview
      • 13.3.2.5. Strategic Overview
    • 13.3.3. Novartis AG
      • 13.3.3.1. Company Overview
      • 13.3.3.2. Product Portfolio
      • 13.3.3.3. SWOT Analysis
      • 13.3.3.4. Financial Overview
      • 13.3.3.5. Strategic Overview
    • 13.3.4. Celgene Corporation
      • 13.3.4.1. Company Overview
      • 13.3.4.2. Product Portfolio
      • 13.3.4.3. SWOT Analysis
      • 13.3.4.4. Financial Overview
      • 13.3.4.5. Strategic Overview
    • 13.3.5. Takeda Pharmaceuticals Company Limited
      • 13.3.5.1. Company Overview
      • 13.3.5.2. Product Portfolio
      • 13.3.5.3. SWOT Analysis
      • 13.3.5.4. Financial Overview
      • 13.3.5.5. Strategic Overview
    • 13.3.6. Incyte Corporation
      • 13.3.6.1. Company Overview
      • 13.3.6.2. Product Portfolio
      • 13.3.6.3. SWOT Analysis
      • 13.3.6.4. Financial Overview
      • 13.3.6.5. Strategic Overview
    • 13.3.7. Sanofi
      • 13.3.7.1. Company Overview
      • 13.3.7.2. Product Portfolio
      • 13.3.7.3. SWOT Analysis
      • 13.3.7.4. Financial Overview
      • 13.3.7.5. Strategic Overview
    • 13.3.8. Bellicum Pharmaceuticals
      • 13.3.8.1. Company Overview
      • 13.3.8.2. Product Portfolio
      • 13.3.8.3. SWOT Analysis
      • 13.3.8.4. Financial Overview
      • 13.3.8.5. Strategic Overview
    • 13.3.9. GSK plc
      • 13.3.9.1. Company Overview
      • 13.3.9.2. Product Portfolio
      • 13.3.9.3. SWOT Analysis
      • 13.3.9.4. Financial Overview
      • 13.3.9.5. Strategic Overview

List of Tables

  • Table 01: Global Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017-2031
  • Table 02: Global Thalassemia Treatment Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 03: North America Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 04: North America Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017-2031
  • Table 05: Europe Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 06: Europe Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017-2031
  • Table 07: Asia Pacific Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 08: Asia Pacific Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017-2031
  • Table 09: Latin America Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Latin America Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017-2031
  • Table 11: Middle East & Africa Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 12: Middle East & Africa Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017-2031

List of Figures

  • Figure 01: Global Thalassemia Treatment Market Size (US$ Mn) and Distribution (%), by Region, 2022-2031
  • Figure 02: Global Thalassemia Treatment Market Revenue (US$ Mn), by Treatment Type, 2022
  • Figure 03: Global Thalassemia Treatment Market Value Share, by Treatment Type, 2022
  • Figure 04: Global Thalassemia Treatment Market Value Share, by Region, 2022
  • Figure 05: Global Thalassemia Treatment Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 06: Global Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022-2031
  • Figure 07: Global Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 08: Global Thalassemia Treatment Market Value Share Analysis, by Region, 2022-2031
  • Figure 09: Global Thalassemia Treatment Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 10: North America Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 11: North America Thalassemia Treatment Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 12: North America Thalassemia Treatment Market Value Share Analysis, by Country, 2022-2031
  • Figure 13: North America Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022-2031
  • Figure 14: North America Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 15: Europe Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 16: Europe Thalassemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 17: Europe Thalassemia Treatment Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 18: Europe Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022-2031
  • Figure 19: Europe Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 20: Asia Pacific Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 21: Asia Pacific Thalassemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 22: Asia Pacific Thalassemia Treatment Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 23: Asia Pacific Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022-2031
  • Figure 24: Asia Pacific Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 25: Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 26: Latin America Thalassemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 27: Latin America Thalassemia Treatment Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 28: Latin America Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022-2031
  • Figure 29: Latin America Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 30: Middle East & Africa Thalassemia Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 31: Middle East & Africa Thalassemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 32: Middle East & Africa Thalassemia Treatment Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 33: Middle East & Africa Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022-2031
  • Figure 34: Middle East & Africa Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031